Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50

Athira Pharma faces shareholder rights investigations

By Brian Buntz | June 21, 2021

Athira PharmaA growing number of law firms are investigating claims of securities fraud associated with Athira Pharma (NSDQ:ATHA), a clinical-stage biopharma focused on small molecules targeting neurodegeneration.

Its lead therapeutic candidate, ATH-1017, targets dementia associated with Alzheimer’s and Parkinson’s.

Law firms investigating potential securities fraud claims involving the company include the following:

  • Ademi (Milwaukee).
  • Block & Leviton (Boston).
  • Johnson Fistel (San Diego).
  • Portnoy (Los Angeles).
  • Wolf Popper (New York City).

The Bothell, Wash.–based company’s stock fell 39% on June 18 after announcing it was putting Leen Kawas, the firm’s CEO, on temporary leave.

Its share price had stabilized by mid-day trading today, edging up 1% to $11.27.

Earlier this month, Jefferies predicted that Athira shares would rise as much as 50% after FDA decided to approve the Alzheimer’s drug aducanumab from Biogen (NSDQ:BIIB).

An Athira Pharma spokesperson did not immediately reply to a request for comment regarding the securities fraud investigations.

The investigations stem from questions regarding published scientific papers that Kawas co-authored. Researchers have posted several of those questions in the online forum PubPeer, which enables scientists to provide anonymous feedback on published research.

Several scientists, including Elisabeth Bik, a microbiologist known for detecting photo manipulation in scientific papers, have identified potential issues in Bik’s doctoral research at Washington State University.

Financial analysts are uncertain whether Athira’s pipeline is associated with potentially problematic research at Washington State University.

Reviewing such questions in published scientific papers often requires accessing original laboratory results, which is difficult for experiments conducted in past years. For example, Kawas performed her doctoral research more than a decade ago.

Achira had planned to begin a Phase 2 study focusing on ATH-1017 by the end of the year.


Filed Under: Drug Discovery
Tagged With: ATH-1017, Athira Pharma, biopharma, neurodegeneration
 

Tell Us What You Think! Cancel reply

You must be logged in to post a comment.

Related Articles Read More >

Takeda Pharmaceutical in the Drug Discovery & Development Pharma 50
Takeda’s Takhzyro fares well in pediatric hereditary angioedema study
Novartis in the Pharma 50
Novartis to cut up to 8,000 positions
Gilead Sciences in the Drug Discovery & Development Pharma 50
Gilead resubmits application to FDA for twice-yearly HIV drug lenacapavir
George Floyd mural
How the pandemic and George Floyd made clinical trial diversity a priority

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MASSDEVICE
  • DEVICETALKS
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • MEDTECH 100
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50